Advertisement
Biologic disease-modifying antirheumatic drugs (DMARDs), also known as biologic agents, biologic response modifiers, or biologics, work by targeting a particular protein that contributes to rheumatoid arthritis (RA). Currently, four types of biologics are approved to treat RA and are named for the inflammatory proteins they target:
A common but short-term side effect of all biologics is a skin reaction at the injection site. And all biologics increase the risk of infection, although to different degrees. TNF-blockers have been linked to serious fungal infections, tuberculosis (TB), and some cases of nerve damage; infliximab may cause severe allergic reactions; and rituximab has been linked to a rare but life-threatening brain infection.
- TNF-blockers (also called inhibitors) -- adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), and infliximab (Remicade)
- T-cell costimulator -- abatacept (Orencia)
- B-cell inhibitor -- rituximab (Rituxan)
- Interleukin-1 inhibitor -- anakinra (Kineret)
A common but short-term side effect of all biologics is a skin reaction at the injection site. And all biologics increase the risk of infection, although to different degrees. TNF-blockers have been linked to serious fungal infections, tuberculosis (TB), and some cases of nerve damage; infliximab may cause severe allergic reactions; and rituximab has been linked to a rare but life-threatening brain infection.
Continue Learning about Muscoloskeletal Agent
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.